SE512633C2 - Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat - Google Patents
Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltratInfo
- Publication number
- SE512633C2 SE512633C2 SE9702657A SE9702657A SE512633C2 SE 512633 C2 SE512633 C2 SE 512633C2 SE 9702657 A SE9702657 A SE 9702657A SE 9702657 A SE9702657 A SE 9702657A SE 512633 C2 SE512633 C2 SE 512633C2
- Authority
- SE
- Sweden
- Prior art keywords
- hyaluronidase
- medicament
- manufacture
- inflammatory cell
- hyaluronan
- Prior art date
Links
- 108010003272 Hyaluronate lyase Proteins 0.000 title claims abstract description 25
- 102000001974 Hyaluronidases Human genes 0.000 title claims abstract description 25
- 229960002773 hyaluronidase Drugs 0.000 title claims abstract description 25
- 210000004969 inflammatory cell Anatomy 0.000 title claims abstract description 13
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims abstract description 14
- 229940099552 hyaluronan Drugs 0.000 claims abstract description 14
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 14
- 210000000056 organ Anatomy 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000008595 infiltration Effects 0.000 abstract description 2
- 238000001764 infiltration Methods 0.000 abstract description 2
- 238000009825 accumulation Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702657A SE512633C2 (sv) | 1997-07-09 | 1997-07-09 | Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat |
| US09/462,362 US6572855B1 (en) | 1997-07-09 | 1998-05-06 | Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation |
| PCT/SE1998/000831 WO1999002181A1 (en) | 1997-07-09 | 1998-05-06 | Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation |
| AU74618/98A AU741770B2 (en) | 1997-07-09 | 1998-05-06 | Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation |
| ES98921978T ES2267186T3 (es) | 1997-07-09 | 1998-05-06 | Uso de hialuronidasa en la fabricacion de un farmaco para el tratamiento de la inflamacion. |
| JP50850999A JP2002509542A (ja) | 1997-07-09 | 1998-05-06 | 炎症治療用薬剤の製造におけるヒアルロニダーゼの使用 |
| CA002296581A CA2296581A1 (en) | 1997-07-09 | 1998-05-06 | Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation |
| EP98921978A EP0994719B1 (de) | 1997-07-09 | 1998-05-06 | Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen |
| AT98921978T ATE332706T1 (de) | 1997-07-09 | 1998-05-06 | Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen |
| DE69835210T DE69835210T2 (de) | 1997-07-09 | 1998-05-06 | Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen |
| NO20000098A NO20000098D0 (no) | 1997-07-09 | 2000-01-07 | Anvendelse av hyaluronidase ved fremstillingen av et medikament for behandling av inflammasjon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702657A SE512633C2 (sv) | 1997-07-09 | 1997-07-09 | Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9702657D0 SE9702657D0 (sv) | 1997-07-09 |
| SE9702657L SE9702657L (sv) | 1999-01-10 |
| SE512633C2 true SE512633C2 (sv) | 2000-04-17 |
Family
ID=20407703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9702657A SE512633C2 (sv) | 1997-07-09 | 1997-07-09 | Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6572855B1 (de) |
| EP (1) | EP0994719B1 (de) |
| JP (1) | JP2002509542A (de) |
| AT (1) | ATE332706T1 (de) |
| AU (1) | AU741770B2 (de) |
| CA (1) | CA2296581A1 (de) |
| DE (1) | DE69835210T2 (de) |
| ES (1) | ES2267186T3 (de) |
| NO (1) | NO20000098D0 (de) |
| SE (1) | SE512633C2 (de) |
| WO (1) | WO1999002181A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026666A1 (de) * | 2000-05-29 | 2001-12-20 | Gunther Burgard | Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen |
| US6682904B1 (en) * | 2002-08-15 | 2004-01-27 | Deliatroph Pharmaceuticals, Inc. | Specific inhibitors of hyaluronidase 2, and methods of identifying and using same |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| WO2008149428A1 (ja) * | 2007-06-05 | 2008-12-11 | Glycoscience Laboratories, Inc. | 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤 |
| KR20130116386A (ko) | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| US8685462B1 (en) | 2012-09-17 | 2014-04-01 | Biopep Solutions, Inc. | Whole, leech saliva product and applications thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504025D0 (en) * | 1985-02-16 | 1985-03-20 | Biopharm Ltd | Hyaluronidase |
| US5747027A (en) * | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
-
1997
- 1997-07-09 SE SE9702657A patent/SE512633C2/sv not_active IP Right Cessation
-
1998
- 1998-05-06 AU AU74618/98A patent/AU741770B2/en not_active Ceased
- 1998-05-06 CA CA002296581A patent/CA2296581A1/en not_active Abandoned
- 1998-05-06 WO PCT/SE1998/000831 patent/WO1999002181A1/en not_active Ceased
- 1998-05-06 ES ES98921978T patent/ES2267186T3/es not_active Expired - Lifetime
- 1998-05-06 AT AT98921978T patent/ATE332706T1/de not_active IP Right Cessation
- 1998-05-06 JP JP50850999A patent/JP2002509542A/ja active Pending
- 1998-05-06 EP EP98921978A patent/EP0994719B1/de not_active Expired - Lifetime
- 1998-05-06 US US09/462,362 patent/US6572855B1/en not_active Expired - Fee Related
- 1998-05-06 DE DE69835210T patent/DE69835210T2/de not_active Expired - Lifetime
-
2000
- 2000-01-07 NO NO20000098A patent/NO20000098D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU7461898A (en) | 1999-02-08 |
| SE9702657L (sv) | 1999-01-10 |
| SE9702657D0 (sv) | 1997-07-09 |
| WO1999002181A1 (en) | 1999-01-21 |
| NO20000098L (no) | 2000-01-07 |
| US6572855B1 (en) | 2003-06-03 |
| JP2002509542A (ja) | 2002-03-26 |
| DE69835210T2 (de) | 2007-07-05 |
| AU741770B2 (en) | 2001-12-06 |
| EP0994719B1 (de) | 2006-07-12 |
| DE69835210D1 (de) | 2006-08-24 |
| CA2296581A1 (en) | 1999-01-21 |
| ES2267186T3 (es) | 2007-03-01 |
| EP0994719A1 (de) | 2000-04-26 |
| NO20000098D0 (no) | 2000-01-07 |
| ATE332706T1 (de) | 2006-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harris et al. | Verapamil protects against progression of experimental chronic renal failure | |
| US5576287A (en) | Method for treating acute renal disease and failure | |
| Friedman et al. | Pituitary growth hormone essential for regulation of serum cholesterol | |
| Faust et al. | Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice | |
| EP0359259B1 (de) | Verwendung von Inositoltriphosphat zur Herstellung eines Arzneimittels gegen Störungen bei Transplantationen | |
| SE512633C2 (sv) | Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat | |
| EP2085094A2 (de) | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen | |
| Siegemund et al. | The value of volume substitution in patients with septic and haemorrhagic shock with respect to the microcirculation | |
| CA2507595A1 (en) | Use of dextran sulfate in the treatment of instant blood-mediated inflammatory reaction | |
| US4670467A (en) | Method of controlling graft versus host reaction | |
| Vanhorebeek et al. | Intensive insulin therapy in the intensive care unit: update on clinical impact and mechanisms of action | |
| Jakob et al. | Glucose turnover and insulin secretion in dogs with pancreatic allografts | |
| Al Asmari et al. | Gastric antisecretory and antiulcer activity of bovine hemoglobin | |
| JPH09506115A (ja) | 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物 | |
| JP2021165276A (ja) | 化学プール薬剤、注射製剤、内服製剤、輸液製剤および透析装置 | |
| Bellomo | Nutrition in acute renal failure | |
| McGeachin et al. | The in vivo effects of puromycin on amylase levels in the serum, liver, salivary glands, and pancreas of the rat | |
| Ertorer et al. | Hyperbilirubinemia in a renal transplant patient due to cyclosporin A therapy | |
| Hall et al. | Enhancement of somatotrophic hormone-induced hypertensive cardiovascular disease by stress | |
| JPH05320043A (ja) | リポポリサッカライド捕捉剤 | |
| CN1668322A (zh) | 基于用丙二烯氧合酶将脂质过氧化物酶消除的心脏保护疗法 | |
| Balestri et al. | Chronic urea intoxication in dogs | |
| CA2262637C (en) | Use of hyaluronidase | |
| Tiron et al. | Renal dysfunction pathogenetically based pharmacological correction using lipoprotein with sorbitol and haes-LX-5% hyperosmolar colloidal solutions in conditions of thyroid gland burning | |
| US5104898A (en) | Method of preventing graft rejection in solid organ transplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |